Arine, a San Francisco-based next-generation medication intelligence company raises $29 million in a Series B round funding composed of equity and debt financing led by 111° West Capital, with participation from new investors MBX Capital and New Leaf Ventures, and continued support from Katalyst Ventures, reports HIT Consultant.
Founded in 2017, Arine helps health plans substantially decrease the cost of care and improve patient outcomes by reducing medication errors, avoiding complications, and keeping patients out of the hospital.
Arine plans to use the latest funding to advance the capabilities of its platform to enable value-based care at scale, not only for health plans and risk-bearing providers, but also to expand its offerings to other channel partners across the value-based care continuum that can leverage Arine’s medication intelligence to achieve next-level outcomes. Read more.
